Gharagozloo N Z, Brubaker R F
Department of Ophthalmology, Mayo Clinic, Rochester, MN 55905.
Ophthalmology. 1991 Oct;98(10):1543-6. doi: 10.1016/s0161-6420(91)32106-7.
A double-blind, randomized study was undertaken to determine if the alpha-agonist apraclonidine has an additive effect in eyes treated with long-term timolol. Seventeen patients (15 with primary open-angle glaucoma, 1 with pigmentary glaucoma, and 1 glaucoma suspect) on long-term timolol treatment in both eyes received a single dose of apraclonidine in one eye and a placebo in the other. Aqueous flow and intraocular pressure were compared in the treated and untreated eyes. There was no statistically significant difference in pretreatment aqueous flow between the two eyes. When flow in the apraclonidine-treated eyes (1.39 +/- 0.41 microliter/min, mean +/- standard deviation) was compared with that of the untreated eyes (1.66 +/- 0.38 microliter/min), a statistically significant difference was found (P less than 0.01). Apraclonidine reduced intraocular pressure by 1.3 mmHg (P = 0.05). The implications of these findings on the understanding of the mechanism of action of adrenergic drugs in the human eye is discussed.
进行了一项双盲随机研究，以确定α-激动剂阿可乐定在长期使用噻吗洛尔治疗的眼中是否具有相加作用。17例双眼长期使用噻吗洛尔治疗的患者（15例原发性开角型青光眼、1例色素性青光眼和1例青光眼可疑患者），一只眼接受单剂量阿可乐定，另一只眼接受安慰剂。比较治疗眼和未治疗眼的房水流量和眼压。两只眼治疗前的房水流量无统计学显著差异。将阿可乐定治疗眼的流量（1.39±0.41微升/分钟，平均值±标准差）与未治疗眼的流量（1.66±0.38微升/分钟）进行比较时，发现有统计学显著差异（P<0.01）。阿可乐定使眼压降低了1.3 mmHg（P = 0.05）。讨论了这些发现对理解肾上腺素能药物在人眼中作用机制的意义。
